Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.58 |
| ▸ | NPC1 | O15118 | 4/20 | 0.56 |
| ▸ | RAB9A | P51151 | 4/20 | 0.56 |
| ▸ | MAPT | P10636 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.55 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.55 |
| ▸ | PDK3 | Q15120 | 1/20 | 0.55 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.55 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL712088 | 0.86 | L3MBTL1 (0.63) | L3MBTL1MEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL20981664 | 0.85 | L3MBTL1 (0.82) | L3MBTL1NPSR1SMN1; SMN2NPC1RAB9A | |
| SCHEMBL10277409 | 0.85 | L3MBTL1 (0.61) | L3MBTL1MEN1KMT2ANPSR1ALDH1A1 | |
| SCHEMBL7193391 | 0.85 | L3MBTL1 (0.61) | L3MBTL1NPSR1ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL3798155 | 0.84 | NPSR1 (0.81) | L3MBTL1MEN1KMT2ANPSR1TDP1 | |
| SCHEMBL19317529 | 0.84 | L3MBTL1 (0.54) | L3MBTL1MEN1KMT2AALDH1A1SMN1; SMN2 | |
| SCHEMBL6931963 | 0.83 | KMT2A (0.60) | MEN1KMT2ANPSR1TDP1ALDH1A1 | |
| SCHEMBL2456608 | 0.81 | L3MBTL1 (0.75) | L3MBTL1NPSR1ALDH1A1SMN1; SMN2NPC1 | |
| SCHEMBL5546919 | 0.81 | L3MBTL1 (0.70) | L3MBTL1MEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL7428282 | 0.80 | MAPT (0.60) | L3MBTL1MEN1KMT2AALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021129841-A1 | COMPOUND USED AS RET KINASE INHIBITOR AND APPLICATION THEREOF | 浙江同源康医药股份有限公司 | 2021-07-01 | — | — | WO | disclosed |
| US-8158632-B2 | Pyrazolo[1,5-a]pyrimidines, processes, uses and compositions | FERRER INTERNACIONAL, S.A. (ES) | 2012-04-17 | — | — | US | disclosed |
| US-8034747-B2 | Photolabile compound, oligomer probe array and substrate for oligomer probe array containing the same, and manufacturing method of the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-10-11 | — | — | US | disclosed |
| US-8034747-B2 | Photolabile compound, oligomer probe array and substrate for oligomer probe array containing the same, and manufacturing method of the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2011-10-11 | — | — | US | disclosed |
| US-7947688-B2 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL, S.A. (ES) | 2011-05-24 | — | — | US | disclosed |
| US-7947688-B2 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL, S.A. (ES) | 2011-05-24 | — | — | US | disclosed |
| US-7947688-B2 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL, S.A. (ES) | 2011-05-24 | — | — | US | disclosed |
| EP-1956028-B1 | Photolabile compound, oligomer probe array and substrate for oligomer probe array containing the same, and manufacturing method of the same | SAMSUNG ELECTRONICS CO LTD (KR) | 2011-05-18 | — | — | EP | disclosed |
| US-20090264448-A1 | PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS | FERRER INTERNATIONAL, S.A. (ES) | 2009-10-22 | — | — | US | disclosed |
| US-7566773-B2 | Photolabile compound and substrate for oligomer probe array with the same | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2009-07-28 | — | — | US | disclosed |
| US-20080057489-A1 | Photolabile Compound and Substrate for Oligomer Probe Array with the Same | SAMSUNG ELECTRONICS CO., LTD (KR) | 2008-03-06 | — | — | US | disclosed |
| US-20080057489-A1 | Photolabile Compound and Substrate for Oligomer Probe Array with the Same | SAMSUNG ELECTRONICS CO., LTD (KR) | 2008-03-06 | — | — | US | disclosed |
| US-20060270690-A1 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | FERRER INTERNACIONAL S.A. (ES) | 2006-11-30 | — | — | US | disclosed |
| CN-1829719-A | N- [ 3- (3-substituted-pyrazolo [1, 5-a ] pyrimidin-7-yl) phenyl ] -sulfonamides, compositions thereof, and related methods | FERRER INT (ES) | 2006-09-06 | — | — | CN | disclosed |
| WO-2006084835-A1 | N-(3-(IMIDAZO [1,5-A]PYRIMIDIN-4-YL)PHENYL]-SULFONAMIDES AND N-[3-(IMIDAZO[1,5-A]PYRIMIDIN-4-YL)-PHENYL]-CARBOXAMIDES AND THEIR USE AS GABAA RECEPTOR MODULATORS | FERRER INTERNACIONAL, S. A. (ES) | 2006-08-17 | — | — | WO | disclosed |
| EP-1648897-A1 | N- [3-(3-SUBSTITUTED-PYRAZOLO[1,5-A] PYRIMIDIN-7-YL) PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2006-04-26 | — | — | EP | disclosed |
| WO-2005014597-A1 | N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
| WO-2005014597-A1 | N-[3-(3-SUBSTITUTED-PYRAZOLO[1,5-a]PYRIMIDIN-7-YL)PHENYL]-SULFONAMIDES, AND COMPOSITIONS, AND METHODS RELATED THERETO | FERRER INTERNACIONAL, S.A. (ES) | 2005-02-17 | — | — | WO | disclosed |
| US-4053470-A | BACTERICIDES, ANTIBIOTICS | PARKE, DAVIS & COMPANY (US) | 1977-10-11 | — | — | US | disclosed |
| US-3954734-A | PENICILLIN AND CEPHALOSPORIN TYPE | PARKE, DAVIS & COMPANY | 1976-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060270690-A1 | N-[3-(3-substituted-pyrazolo[1,5-a]pyrimidin-7-yl)phenyl]-sulfonamides, and compositions, and methods related thereto | GABRA2, GABRA1, GABRA3 | L3MBTL1 4498/4885MEN1 3821/4885KMT2A 2283/4885 |
| US-20080057489-A1 | Photolabile Compound and Substrate for Oligomer Probe Array with the Same | APBA1, B3GNT2, PCNA | L3MBTL1 2609/4885MEN1 3145/4885KMT2A 3308/4885 |
| US-20090264448-A1 | PYRAZOLO[1,5-A]PYRIMIDINES, PROCESSES, USES AND COMPOSITIONS | P2RX5, GABRA5, P2RX1 | L3MBTL1 3610/4885MEN1 4525/4885KMT2A 559/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.